BioChem Pharma of Canada is planning to play a major part in theconsolidation of the pharmaceutical industry by possibly acquiring "up to a $1-billion company" in the USA, according to its chief executive Francesco Bellini.
Dr Bellini told The Globe and Mail that "in Canada, we don't see companies that fit our technology base" and a deal in the USA is likely, though BioChem is also interested in expanding its operations in Europe. He said that the company is looking to grow "in the fields we know best like cancer, antiviral and bacterial," adding that he does not want to diversify "because then I can't compete with the multinationals." Biochem is planning to exit its diagnostics businesses in order to focus on its more profitable therapeutic divisions which have developed drugs such as lamivudine.
BioChem is also planning to invest $200-$300 million in developing its vaccine group, which Dr Bellini claims "will make us famous in five years." The group's first product, a nasally-delivered vaccine for influenza, is expected to be launched in two years' time.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze